Literature DB >> 20938757

Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems.

Elena Grabski1, Zoe Waibler, Silke Schüle, Björn-Philipp Kloke, Linda Y Sender, Sylvia Panitz, Klaus Cichutek, Matthias Schweizer, Ulrich Kalinke.   

Abstract

Lentiviral gene transfer vectors are suitable for genetically modifying non-cycling primary human cells. In this study, we analyzed transduced human dendritic cells (DC) generated by the use of three different GFP-encoding lentiviral vectors, HIV-2 ROD A Δenv-GFP (ROD A), SIVsmm PBj ΔE EGFP (PBj), and SIVmac ΔE EGFP (SIVmac). CD14+ monocytes were isolated from buffy coat, transduced, and differentiated to immature and mature DC. Cytofluometric analysis of DC revealed high transduction efficiencies at MOI 1 for simian immunodeficiency virus (SIV)-derived vectors PBj and SIVmac ranging between 80-90 and 70-90%, respectively. In contrast, transduction with ROD A resulted only in approximately 30%-positive DC at the same MOI. Of note, none of the analyzed vectors affected expression of maturation and/or activation markers. Moreover, transduction with PBj or SIVmac did not induce significant cytokine responses whereas ROD A transduction stimulated weak interferon-alpha responses. SIVmac transduced DC showed normal phagocytosis of antigen and normal allo T cell stimulatory capacity when compared with untreated DC. Thus, the SIVmac lentiviral transduction vector is suitable for efficient genetic modification of human DC without affecting phenotype or function and thus qualifies this vector as a versatile tool for use in basic research.

Entities:  

Mesh:

Year:  2011        PMID: 20938757     DOI: 10.1007/s12033-010-9340-z

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  15 in total

1.  Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity.

Authors:  H Jonuleit; T Tüting; J Steitz; J Brück; A Giesecke; K Steinbrink; J Knop; A H Enk
Journal:  Gene Ther       Date:  2000-02       Impact factor: 5.250

2.  Stable transduction of primary human monocytes by simian lentiviral vector PBj.

Authors:  Michael D Mühlebach; Nina Wolfrum; Silke Schüle; Ulrich Tschulena; Ralf Sanzenbacher; Egbert Flory; Klaus Cichutek; Matthias Schweizer
Journal:  Mol Ther       Date:  2005-09-16       Impact factor: 11.454

3.  Ex vivo generation of genetically modified dendritic cells for immunotherapy: implications of lymphocyte contamination.

Authors:  N Chinnasamy; J S Treisman; M K Oaks; J P Hanson; D Chinnasamy
Journal:  Gene Ther       Date:  2005-02       Impact factor: 5.250

4.  Role of HIV-2 envelope in Lv2-mediated restriction.

Authors:  Sandra Reuter; Patrick Kaumanns; Sabine B Buschhorn; Matthias T Dittmar
Journal:  Virology       Date:  2005-02-05       Impact factor: 3.616

5.  Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus.

Authors:  T Schnell; P Foley; M Wirth; J Münch; K Uberla
Journal:  Hum Gene Ther       Date:  2000-02-10       Impact factor: 5.695

6.  Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells.

Authors:  Caroline Goujon; Vanessa Arfi; Thomas Pertel; Jeremy Luban; Julia Lienard; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

7.  alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.

Authors:  Robbie B Mailliard; Anna Wankowicz-Kalinska; Quan Cai; Amy Wesa; Catharien M Hilkens; Martien L Kapsenberg; John M Kirkwood; Walter J Storkus; Pawel Kalinski
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

8.  CD40 ligand-independent B cell activation revealed by CD40 ligand-deficient T cell clones: evidence for distinct activation requirements for antibody formation and B cell proliferation.

Authors:  P Lane; C Burdet; F McConnell; A Lanzavecchia; E Padovan
Journal:  Eur J Immunol       Date:  1995-06       Impact factor: 5.532

9.  Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain.

Authors:  B Liehl; J Hlavaty; R Moldzio; Z Tonar; H Unger; B Salmons; W H Günzburg; M Renner
Journal:  Gene Ther       Date:  2007-07-05       Impact factor: 5.250

10.  Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj.

Authors:  Silke Schüle; Björn-Philipp Kloke; Julia K Kaiser; Sabine Heidmeier; Sylvia Panitz; Nina Wolfrum; Klaus Cichutek; Matthias Schweizer
Journal:  PLoS One       Date:  2009-09-21       Impact factor: 3.240

View more
  10 in total

1.  De novo hem- and lymphangiogenesis by endothelial progenitor and mesenchymal stem cells in immunocompetent mice.

Authors:  Kerstin Buttler; Muhammad Badar; Virginia Seiffart; Sandra Laggies; Gerhard Gross; Jörg Wilting; Herbert A Weich
Journal:  Cell Mol Life Sci       Date:  2013-09-01       Impact factor: 9.261

2.  Lentivirus transduction of human osteoclast precursor cells and differentiation into functional osteoclasts.

Authors:  Margaret L Ramnaraine; Wendy E Mathews; Denis R Clohisy
Journal:  Bone       Date:  2011-10-01       Impact factor: 4.398

Review 3.  New approaches to the development of adenoviral dendritic cell vaccines in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic
Journal:  Curr Opin Investig Drugs       Date:  2010-12

4.  Modulation of TAP-dependent antigen compartmentalization during human monocyte-to-DC differentiation.

Authors:  Marius Döring; Hanna Blees; Nicole Koller; Sabine Tischer-Zimmermann; Mathias Müsken; Frederik Henrich; Jennifer Becker; Elena Grabski; Junxi Wang; Hans Janssen; Werner Zuschratter; Jacques Neefjes; Frank Klawonn; Britta Eiz-Vesper; Robert Tampé; Ulrich Kalinke
Journal:  Blood Adv       Date:  2019-03-26

5.  Expression of the human cytomegalovirus UL11 glycoprotein in viral infection and evaluation of its effect on virus-specific CD8 T cells.

Authors:  Ildar Gabaev; Endrit Elbasani; Stefanie Ameres; Lars Steinbrück; Richard Stanton; Marius Döring; Tihana Lenac Rovis; Ulrich Kalinke; Stipan Jonjic; Andreas Moosmann; Martin Messerle
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

6.  Ultrasensitive quantification of TAP-dependent antigen compartmentalization in scarce primary immune cell subsets.

Authors:  Hanna Fischbach; Marius Döring; Daphne Nikles; Elisa Lehnert; Christoph Baldauf; Ulrich Kalinke; Robert Tampé
Journal:  Nat Commun       Date:  2015-02-06       Impact factor: 14.919

7.  Tropism, intracerebral distribution, and transduction efficiency of HIV- and SIV-based lentiviral vectors after injection into the mouse brain: a qualitative and quantitative in vivo study.

Authors:  Juraj Hlavatý; Zbyněk Tonar; Matthias Renner; Sylvia Panitz; Helga Petznek; Matthias Schweizer; Silke Schüle; Björn-Philipp Kloke; Rudolf Moldzio; Kirsti Witter
Journal:  Histochem Cell Biol       Date:  2017-04-10       Impact factor: 4.304

8.  Nanoscale organization of the MHC I peptide-loading complex in human dendritic cells.

Authors:  Nicole Koller; Philipp Höllthaler; Martina Barends; Marius Döring; Christoph Spahn; Verónica Durán; Bibiana Costa; Jennifer Becker; Mike Heilemann; Ulrich Kalinke; Robert Tampé
Journal:  Cell Mol Life Sci       Date:  2022-08-10       Impact factor: 9.207

9.  Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.

Authors:  Liang Xiao; Kye-Il Joo; Matthew Lim; Pin Wang
Journal:  PLoS One       Date:  2012-11-06       Impact factor: 3.240

10.  Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells.

Authors:  Stephanie Vogel; Elena Grabski; Daniela Buschjäger; Frank Klawonn; Marius Döring; Junxi Wang; Erika Fletcher; Ingo Bechmann; Torsten Witte; Martin Durisin; Burkhart Schraven; Sara M Mangsbo; Kurt Schönfeld; Niklas Czeloth; Ulrich Kalinke
Journal:  Sci Rep       Date:  2015-12-16       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.